यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - antineoplastična sredstva - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.

यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastična sredstva - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

laboratoire hra pharma - ulipristal - kontracepcija, postcoital - spolni hormoni i modulatori genitalnog sustava , sredstva za hitne kontracepcije - hitna kontracepcija unutar 120 sati (pet dana) nezaštićenog seksualnog odnosa ili neuspjeha kontracepcije.

यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

alexion europe sas - sebelipaza alfa - metabolizam lipida, urođene pogreške - drugi gastrointestinalni trakt i metabolizam, lijekovi, - kanuma je indiciran za dugoročnu zamjensku enzimsku terapiju (ert) u bolesnika svih dobnih skupina s nedostatkom lipaze lizosomalne kiseline (lal).

यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

sanofi b.v. - sevelamer karbonat - hyperphosphatemia; renal dialysis - svi ostali terapeutski proizvodi - Севеламера kalcijev winthrop je dizajniran za kontrolu hyperphosphataemia kod odraslih pacijenata koji primaju гемодиализ ili перитонеальный dijaliza. Севеламера kalcijev winthrop također je prikazano za kontrolu hyperphosphataemia u odraslih bolesnika s kroničnom bolešću bubrega bez dijalizu s fosfora u serumu > 1. 78 mmol / l. Севеламера kalcijev winthrop treba koristiti u okviru nekoliko terapijskih pristupa koji se mogu uključiti dodataka kalcija, 1,25-дигидрокси-vitamin d3 ili jedan od njegovih analoga za praćenje razvoja bolesti bubrega канальцах .

यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

amarin pharmaceuticals ireland limited - icosapent ethyl - dislipidemije - sredstva za modifikaciju lipida - indicated to reduce cardiovascular risk as an adjunct to statin therapy.

यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

stada arzneimittel ag - budesonide, micronised - glomerulonephritis, iga - antidiarrheal sredstva, uzročnika crijevnih protuupalnih / antiinfective - kinpeygo is indicated for the treatment of primary immunoglobulin a (iga) nephropathy (igan) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (upcr) ≥1. 5 g/gram.

यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

rad neurim pharmaceuticals eec sarl - melatonin - poremećaji uvođenja i održavanja spavanja - psycholeptics - melatonin neurim is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.

यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

amryt pharmaceuticals dac - lomitapide - hiperkolesterolemija - sredstva za modifikaciju lipida - lojuxta je indicirana kao dodatak prehrani low‑fat i drugih lipid‑lowering lijekova s ili bez afereze najniža gustoće lipoproteina (ldl) u odraslih bolesnika s homozigotni obiteljska hiperkolesterolemija (hofh). genetičko potvrdu hofh mora biti ispitan na mogućnosti. drugi oblici primarne гиперлипопротейнемия i sekundarni uzroci гиперхолестеринемии (e. nephrotic sindrom, hipotireoza) moraju biti isključeni.

यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab - karcinom, ne-malih stanica pluća - Антинеопластические i иммуномодулирующие agenti, monoklonsko antitijelo - nivolumab bms je indiciran za liječenje lokalno avanziranog ili metastatskog skvamoznog ne-malih stanica raka pluća (nsclc) nakon prethodne kemoterapije kod odraslih.